Arjona-Sanchez, A.Martinez-López, A.Moreno-Montilla, M.T.Mulsow, J.Lozano-Lominchar, P.Martínez-Torres, B.Rau B.2024-05-192024-05-1920230748-7983https://doi.org/10.1016/j.ejso.2023.03.206https://hdl.handle.net/20.500.12713/4494Background: Pseudomyxoma peritonei (PMP) is a rare malignant disease. Adding of the Ki67 proliferation index to the PSOGI PMP classification provided two different subcategories of the extensive HG-PMP group (HG-PMP ?15% and HG-PMP >15%) with different survival in a previous unicentric study. This study aims to carry out an external and multicentre validation of this new proposed classification. Method: It was a prospective analysis of samples from a historical and international cohort of patients. A representative area with higher cellular density was used to determine the Ki67%. The Ki67 proliferation index (%) was determined in all the HG-PMP patients. A Cox proportional hazard models and multivariable COX models were used. The Kaplan–Meier method and the two-tailed log-rank test were used to analyse the effect of different PSOGI-Ki67 categories on OS and DFS. Its predictive accuracy was analysed using Harrel's C-index and the ROC curve. The calibration was performed using the calibration plots matching. Results: After exclusions, 349 patients were available for analysis. The 5-years OS were 86% for LG-PMP, 59% for HG-PMP?15, 38% for HG-PMP>15 and 42% for SRC-PMP (p = 0.0001). The 5-years DFS were 49% for LG-PMP, 35% for HG-PMP?15, 16% for HG-PMP>15 and 18% SRC-PMP (p = 0.0001). The discrimination capability of PSOGI-Ki67 was validated. Conclusion: the PSOGI-Ki67 classification discriminates and predicts the OS and DFS in patients with PMP dividing the HG-PMP category into two well-defined sub-categories. The Ki67 proliferation index should be incorporated routinely in the pathology report for these patients. © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncologyeninfo:eu-repo/semantics/closedAccessAntineoplastic AgentKi 67 AntigenKi 67 AntigenAdjuvant ChemotherapyAdultAgedArticleCancer ClassificationCancer PatientCancer SurvivalCell DensityCohort AnalysisControlled StudyCytoreductive SurgeryDisease Free SurvivalFemaleFollow UpHumanHuman TissueHyperthermic İntraperitoneal ChemotherapyLabeling İndexMajor Clinical StudyMaleMedian Survival TimeMulticenter StudyNeoadjuvant ChemotherapyOverall SurvivalPeritoneum PseudomyxomaPredictive ValueProliferation İndexProspective StudyReceiver Operating CharacteristicSurvival RateSystemic TherapyTissue SectionValidation ProcessClinical TrialPathologyPeritoneum PseudomyxomaPeritoneum TumorPrognosisProportional Hazards ModelRetrospective StudyHumansKi-67 AntigenPeritoneal NeoplasmsPrognosisProportional Hazards ModelsPseudomyxoma PeritoneiRetrospective StudiesArticle49814811488369352222-s2.0-8515030826810.1016/j.ejso.2023.03.206N/A